)
Overview
<ul>
<li>Biotechnology firm’s Q4 revenue beat analyst expectations</li>
<li>Net income and income from operations missed analyst estimates</li>
<li>Company advancing RNA medicines pipeline with multiple clinical trials in 2026</li>
</ul>
Outlook
<ul>
<li>Wave plans to initiate Phase 2a trial for WVE-007 in 1H 2026</li>
<li>Company expects regulatory feedback on WVE-006 approval pathway mid-2026</li>
<li>Wave aims to file CTA for WVE-008 for liver disease in 2026</li>
</ul>
Result Drivers
<ul>
<li>OBESITY TREATMENT - WVE-007 showed promising interim results in fat loss comparable to GLP-1, with muscle preservation, supporting its potential as a transformative obesity treatment</li>
<li>AATD ADVANCEMENTS - WVE-006 achieved key treatment goals for AATD, with dynamic AAT production and favorable safety, advancing towards potential accelerated approval</li>
<li>LIVER DISEASE FOCUS - WVE-008 is advancing for PNPLA3 I148M liver disease, with preparations for a clinical trial application in 2026 Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q4 Beat $17.24 $16.30
Revenue mln mln (16
Analysts
)
<h3>Q4 EPS -$0.30</h3>
Q4 Net Miss -$53.18 -$45.92
Income mln mln (15
Analysts
)
Q4 Miss -$56.47 -$48.53
Income mln mln (15
from Analysts
Operatio )
ns
Q4 Miss -$53.18 -$45.67
Pretax mln mln (14
Profit Analysts
)
<h3>Q4 $73.71</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 16 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for WAVE Life Sciences Ltd is $32.50, about 123.5% above its February 25 closing price of $14.54 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

ARKG

SBIO

Reuters

Wave Life Sciences

iShares Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Bioshares Biotech Clinical Trials Fd

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Wave Life Sciences Q4 revenue beats analyst expectations